VANCOUVER, British Columbia, Oct. 18, 2010 (GLOBE NEWSWIRE) -- biOasis Technologies Inc. (TSX-V:BTI) has received a final report detailing results achieved within the Collaborative Research project with The University of British Columbia (UBC) that was announced by the Company on June 2, 2009. The report indicates that p97 (see About Transcend™ below) was more readily transported across the blood-brain barrier and accumulated to a significantly greater degree in brain tissue than did the anti-amyloid ß IgG that was used as an experimental control. Further, it was observed that p97 accumulated in the brain more rapidly than IgG and to a much higher degree that has been reported previously. It was also demonstrated that the primary route of elimination of p97 from the body was via the kidney.
